| Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity M Soethoudt, U Grether, J Fingerle, TW Grim, F Fezza, L De Petrocellis, ... Nature communications 8 (1), 13958, 2017 | 321 | 2017 |
| Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors DB Finlay, KJ Sircombe, M Nimick, C Jones, M Glass Frontiers in pharmacology 11, 359, 2020 | 99 | 2020 |
| Gαs signalling of the CB1 receptor and the influence of receptor number DB Finlay, EE Cawston, NL Grimsey, MR Hunter, A Korde, VK Vemuri, ... British Journal of Pharmacology 174 (15), 2545-2562, 2017 | 91 | 2017 |
| GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine DB Finlay, WR Joseph, NL Grimsey, M Glass PeerJ 4, e1835, 2016 | 85 | 2016 |
| Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence MS Ibsen, DB Finlay, M Patel, JA Javitch, M Glass, NL Grimsey Frontiers in pharmacology 10, 350, 2019 | 78 | 2019 |
| Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA DB Finlay, JJ Manning, MS Ibsen, CE Macdonald, M Patel, JA Javitch, ... ACS chemical neuroscience 10 (10), 4350-4360, 2019 | 53 | 2019 |
| Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists M Patel, JJ Manning, DB Finlay, JA Javitch, SD Banister, NL Grimsey, ... Biochemical Pharmacology 175, 113871, 2020 | 51 | 2020 |
| 100 years of modelling ligand–receptor binding and response: A focus on GPCRs DB Finlay, SB Duffull, M Glass British journal of pharmacology 177 (7), 1472-1484, 2020 | 51 | 2020 |
| Biased agonism at the cannabinoid receptors–evidence from synthetic cannabinoid receptor agonists M Patel, DB Finlay, M Glass Cellular Signalling 78, 109865, 2021 | 35 | 2021 |
| Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias JJ Manning, HM Green, M Glass, DB Finlay Neuropharmacology 193, 108611, 2021 | 30 | 2021 |
| Model‐free and kinetic modelling approaches for characterising non‐equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors X Zhu, DB Finlay, M Glass, SB Duffull British Journal of Pharmacology 176 (14), 2593-2607, 2019 | 29 | 2019 |
| Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling X Zhu, DB Finlay, M Glass, SB Duffull British journal of pharmacology 177 (15), 3449-3463, 2020 | 18 | 2020 |
| Real-time measurement of cannabinoid receptor-mediated cAMP signaling MR Hunter, DB Finlay, CE Macdonald, EE Cawston, NL Grimsey, M Glass Methods in enzymology 593, 43-59, 2017 | 18 | 2017 |
| In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018 TF Gamage, DG Barrus, RC Kevin, DB Finlay, TW Lefever, PR Patel, ... Pharmacology Biochemistry and Behavior 193, 172918, 2020 | 17 | 2020 |
| An evaluation of the operational model when applied to quantify functional selectivity X Zhu, DB Finlay, M Glass, SB Duffull British journal of pharmacology 175 (10), 1654-1668, 2018 | 17 | 2018 |
| Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials M Haney, M Vallée, S Fabre, S Collins Reed, M Zanese, G Campistron, ... Nature Medicine 29 (6), 1487-1499, 2023 | 15 | 2023 |
| A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models CA Mielnik, KS Sugamori, DB Finlay, HHA Thorpe, M Schapira, ... Neuropsychopharmacology 46 (2), 413-422, 2021 | 11 | 2021 |
| Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1 … J Markham, E Sparkes, R Boyd, S Chen, JJ Manning, D Finlay, F Lai, ... ACS Chemical Neuroscience 13 (8), 1281-1295, 2022 | 10 | 2022 |
| Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence JJ Manning, G Rawcliffe, DB Finlay, M Glass British journal of pharmacology 180 (3), 369-382, 2023 | 9 | 2023 |
| Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases M Patel, C Matti, NL Grimsey, DF Legler, JA Javitch, DB Finlay, M Glass British journal of pharmacology 179 (10), 2223-2239, 2022 | 9 | 2022 |
